Lenvatinib, a kinase inhibitor, exerts its antitumor effects by inhibiting angiogenesis, which is important for tumor growth and metastasis, mainly by inhibiting VEGFR1–3 and FGFR1–4. This evidence concerns the gene FGFR1 and neoplasm.